Tehran hit by unprecedented Israeli strikes as U.S. peace talks stall and Hormuz deadline pushed again
Read More 5 minute read Pharma Industry News Investors watch Nuvalent ahead of pivotal neladalkib ALKOVE-1 topline data in resistant ALK-positive NSCLC Nuvalent will unveil pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive NSCLC on November 17. Explore why investors believe this readout could redefine targeted lung cancer care. bySoujanya RaviNovember 15, 2025